Business News • PR NewsWire • Phase III Novartis Data Show Potential Benefit of Afinitor® Plus Sandostatin® LAR Depot in Patients with Advanced Carcinoid Tumors

Phase III Novartis Data Show Potential Benefit of Afinitor® Plus Sandostatin® LAR Depot in Patients with Advanced Carcinoid Tumors

Phase III Novartis Data Show Potential Benefit of Afinitor® Plus Sandostatin® LAR Depot in Patients with Advanced Carcinoid Tumors

EAST HANOVER, N.J., Oct. 11 /PRNewswire/ -- A Novartis Pharmaceuticals Corporation ("Novartis") Phase III study of Afinitor® (everolimus) tablets in combination with Sandostatin® LAR Depot (octreotide acetate for injectable suspension) extended median progression-free survival (PFS), or ti

View More : http://www.prnewswire.com/news-releases/phase-iii-novartis-data-show-potential-benefit-of-afinitor-plus-sandostatin-lar-...

Releted News by prnewswire

Amazon.co.uk Announces Free Delivery for Customers in 17 Countries Across Europe

UK's Largest Electrical Retailer Launches New Range of 'No Frills' Appliances

Verizon Business Expands Asia-Pacific Cloud Capabilities

Phase III Novartis Data Show Potential Benefit of Afinitor® Plus Sandostatin® LAR Depot in Patients with Advanced Carcinoid Tumors

ARM and SMIC Extend Comprehensive Product Portfolio of Free Libraries of Physical IP to 65nm and 40nm LL Process Technology

The First Fantasy Trading Game From ETX Capital Launches on Facebook